Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey.

[1]  D. Bacquer,et al.  SURF – SUrvey of Risk Factor management: first report of an international audit , 2014, European journal of preventive cardiology.

[2]  Ž. Reiner.  Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  Ž. Reiner.  Statins in the primary prevention of cardiovascular disease , 2013, Nature Reviews Cardiology.

[4]  Ž. Reiner,et al.  Prevalence and types of persistent dyslipidemia in patients treated with statins , 2013, Croatian medical journal.

[5]  G. Mancia,et al.  Prevention of cardiovascular disease guided by total risk estimations − challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy , 2012, European journal of preventive cardiology.

[6]  Ž. Reiner,et al.  Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality , 2012, Current Cardiology Reports.

[7]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[8]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[9]  Ž. Reiner,et al.  The perception and knowledge of cardiovascular risk factors among medical students , 2012, Croatian medical journal.

[10]  J. Saver,et al.  Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. , 2011, Atherosclerosis.

[11]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[12]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[13]  G. Watts,et al.  Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient , 2011, Heart.

[14]  P. Touboul,et al.  Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis , 2011, Journal of cardiovascular pharmacology.

[15]  Ž. Reiner,et al.  Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. , 2010, Atherosclerosis.

[16]  Ž. Reiner,et al.  Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. , 2010, Preventive medicine.

[17]  K. Kotseva,et al.  Management of overweight and obese patients with coronary heart disease across Europe , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[18]  Ž. Reiner.  Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & clinical pharmacology.

[19]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[20]  Ž. Reiner.  How to improve cardiovascular diseases prevention in Europe? , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[21]  J. Kastelein,et al.  Triglycerides and Cardiovascular Risk , 2009, Current cardiology reviews.

[22]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[23]  K. Kotseva,et al.  Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries , 2009, The Lancet.

[24]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[25]  G. De Backer,et al.  Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. , 2008, Atherosclerosis.

[26]  Ž. Reiner,et al.  The burden of hyperlipidaemia and diabetes in cardiovascular diseases , 2007, Fundamental & clinical pharmacology.

[27]  M. Pencina,et al.  Increasing trends in incidence of overweight and obesity over 5 decades. , 2007, The American journal of medicine.

[28]  Ž. Reiner,et al.  Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study) , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[29]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[30]  J. Collin,et al.  Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. , 2005, British journal of clinical pharmacology.

[31]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[32]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). , 2004, Atherosclerosis.

[33]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[34]  G. De Backer,et al.  Potential for cholesterol lowering in secondary prevention of coronary heart disease in europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events. , 2000, Atherosclerosis.

[35]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[36]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[37]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.

[38]  R. Bawol,et al.  Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. , 1980, The New England journal of medicine.

[39]  Jonathan E. Dickerson,et al.  Supplementary webappendix , 2013 .

[40]  D. Atar,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invit , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[41]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .